Citations

Clear

3057 citation(s) found for "Cd, Johnson".

CAMKV Autoimmune Paraneoplastic Encephalitis (N1.003)
Gilligan, Michael , Lesnick, Connie , Shah, Maulik , Wittenborn, John S. , Hinson, Shannon R., Mills, John R. , Ζεκερίδου, Αναστασία , Bradshaw, Michael, Ladha, Shafeeq , Wittenborn, John, Dubey, Divyanshu , Pittock, Sean J. , McKeon, Andrew

Mayo Clinic

Neurology | April 9, 2024 | Volume: 102 | Issue: 7_supplement_1 | Pages: No page available

10.1212/wnl.0000000000204736 Get It

AAPM WGPE report 394: Simulated error training for the physics plan and chart review
Johnson, Perry , Schubert, Leah , Kim, Grace Gwe‐Ya, Faught, Jacqueline, Buckey, C, Luk, Samuel M. H. , Parker, S. , Conroy, Leigh , Schofield, Deborah

Mayo Clinic

Medical Physics | April 8, 2024 | Volume: 51 | Issue: 5 | Pages: 3165-3172

10.1002/mp.17051 | PMID 38588484 Get It

AbstractBackgroundSimulated error training is a method to practice error detection in situations where the occurrence of error is low. Such is the case for the physics plan and chart review where a physicist may check several plans before encountering a significant problem. By simulating potentially hazardous errors, physicists can become familiar with how they manifest and learn from mistakes made during a simulated plan review.PurposeThe purpose of this project was to develop a series of training datasets that allows medical physicists and trainees to practice plan and chart reviews in a way that is familiar and accessible, and to provide exposure to the various failure modes (FMs) encountered in clinical scenarios.MethodsA series of training datasets have been developed that include a variety of embedded errors based on the risk‐assessment performed by American Association of Physicists in Medicine (AAPM) Task Group 275 for the physics plan and chart review. The training datasets comprise documentation, screen shots, and digital content derived from common treatment planning and radiation oncology information systems and are available via the Cloud‐based platform ProKnow.ResultsOverall, 20 datasets have been created incorporating various software systems (Mosaiq, ARIA, Eclipse, RayStation, Pinnacle) and delivery techniques. A total of 110 errors representing 50 different FMs were embedded with the 20 datasets. The project was piloted at the 2021 AAPM Annual Meeting in a workshop where participants had the opportunity to review cases and answer survey questions related to errors they detected and their perception of the project's efficacy. In general, attendees detected higher‐priority FMs at a higher rate, though no correlation was found between detection rate and the detectability of the FMs. Familiarity with a given system appeared to play a role in detecting errors, specifically when related to missing information at different locations within a given software system. Overall, 96% of respondents either agreed or strongly agreed that the ProKnow portal and training datasets were effective as a training tool, and 75% of respondents agreed or strongly agreed that they planned to use the tool at their local institution.ConclusionsThe datasets and digital platform provide a standardized and accessible tool for training, performance assessment, and continuing education regarding the physics plan and chart review. Work is ongoing to expand the project to include more modalities, radiation oncology treatment planning and information systems, and FMs based on emerging techniques such as auto‐contouring and auto‐planning.
Effect of Active Workstations on Neurocognitive Performance and Typing Skills: A Randomized Clinical Trial
Medina‐Inojosa, José R. , Ibarra, Miguel A. Gomez, Medina‐Inojosa, Betsy J. , Supervía, Marta , Jenkins, Sarah M. , Johnson, Lynne L. , Moscoso, Nathalie P Suárez , Bonikowske, Amanda R. , Somers, Virend K. , López-Jiménez, Francisco , Gomez Ibarra, Miguel A, Johnson, Lynne, Suarez, Nathalie P , Bonikowske, Amanda , Somers, Virend K. , Lopez-Jimenez, Francisco , Medina-Inojosa, José R , Medina-Inojosa, Betsy , Johnson, Lynne

Mayo Clinic

Journal of the American Heart Association | April 4, 2024 | Volume: 13 | Issue: 8 | Pages: No page available

10.1161/jaha.123.031228 | PMID 38572691 Get It

Background Extended sedentary behavior is a risk factor for chronic disease and mortality, even among those who exercise regularly. Given the time constraints of incorporating physical activity into daily schedules, and the high likelihood of sitting during office work, this environment may serve as a potentially feasible setting for interventions to reduce sedentary behavior. Methods and Results A randomized cross‐over clinical trial was conducted at an employee wellness center. Four office settings were evaluated on 4 consecutive days: stationary or sitting station on day 1 (referent), and 3 subsequent active workstations (standing, walking, or stepper) in randomized order. Neurocognitive function (Selective Attention, Grammatical Reasoning, Odd One Out, Object Reasoning, Visuospatial Intelligence, Limited‐Hold Memory, Paired Associates Learning, and Digit Span) and fine motor skills (typing speed and accuracy) were tested using validated tools. Average scores were compared among stations using linear regression with generalized estimating equations to adjust standard errors. Bonferroni method adjusted for multiple comparisons. Healthy subjects were enrolled (n=44), 28 (64%) women, mean±SD age 35±11 years, weight 75.5±17.1 kg, height 168.5±10.0 cm, and body mass index 26.5±5.2 kg/m 2 . When comparing active stations to sitting, neurocognitive test either improved or remained unchanged, while typing speed decreased without affecting typing errors. Overall results improved after day 1, suggesting habituation. We observed no major differences across active stations, except decrease in average typing speed 42.5 versus 39.7 words per minute with standing versus stepping ( P =0.003). Conclusions Active workstations improved cognitive performance, suggesting that these workstations can help decrease sedentary time without work performance impairment. Registration URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06240286.
Reliability and Validity of Smartphone Cognitive Testing for Frontotemporal Lobar Degeneration
Staffaroni, Adam M. , Clark, Annie L , Taylor, Jack C. , Heuer, Hilary W. , Wise, Amy B. , Dhanam, Sreya , Wolf, Amy , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rankin, Katherine P. , Clark, David , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Fields, Julie A. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Huey, Edward D. , Masdeu, Joseph C. , Massimo, Lauren , Mendez, Mario F. , Miyagawa, Toji , Pascual, Belén , Pressman, Peter , Ramos, Eliana Marisa , Rascovsky, Katya, Roberson, Erik D. , Wong, Bonnie , Kornak, John , Kremers, Walter K. , Hassenstab, Jason , Kramer, Joel H. , Rosen, Howard J. , Boxer, Adam L. , Apostolova, Liana G. , Barmada, Sami J. , Brushaber, Danielle , Day, Gregg S, Dickerson, Bradford, Faber, Kelley, Fagan, Anne M. , Foroud, Tatiana M., Gavrilova, Ralitza H. , Graff‐Radford, Jonathan , Grant, Ian , Hall, Matthew , Hales, Chadwick M. , Huang, Eric J. , Johnson, Noah R. , Kolander, Tyler, Kwan, Justin , Lago, Argentina Lario , Lavigne, Shannon B., Lee, Suzee, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , McGinnis, Scott, Molden, Joie, Naasan, Georges , Onyike, Chiadi U. , Petrucelli, Leonard , Rademakers, Rosa , Rao, Meghana , Rhoads, Kristoffer , Ritter, Aaron, Rogalskı, Emily , Savica, Rodolfo , Sullivan, Anne C. , Syrjanen, Jeremy M., Weıntraub, Sandra , Wint, Dylan , Yokoyoma, Jennifer, Roberson, Erik , Pascual, Belen , Hassenstab, Jason , Kremers, Walter K , Domoto-Reilly, Kimiko , Barmada, Sami , Sanderson‐Cimino, Mark , Cobigo, Yann , Appleby, Brian S. , Bayram, Ece , Bozoki, Andrea C , Galasko, Douglas , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Jones, David T. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Ramanan, Vijay K. , Tartaglia, Maria Carmela , Miller, Bruce L. , Boeve, Bradley F. , Botha, Hugo , Day, Gregg S, Dickson, Dennis W. , Elahi, Fanny M. , Fong, Jamie , Gendron, Tania F. , Goldman, Jill , Honig, Lawrence S. , Irwin, David J. , Johnson, Noah, Kantarci, Kejal , Knopman, David S. , Léger, Gabriel C. , McMillan, Corey T. , Pantelyat, Alexander , Paolillo, Emily W. , Paulson, Henry L. , Rexach, Jessica E. , Rojas, Julio C. , Seeley, William W. , Snyder, Allison , Sullivan, Anne C., Tipton, Philip W. , Vandebergh, Marijne , Toga, Arthur W. , VandeVrede, Lawren , Wszołek, Zbigniew K.

Mayo Clinic

JAMA Network Open | April 1, 2024 | Volume: 7 | Issue: 4 | Pages: e244266

10.1001/jamanetworkopen.2024.4266 | PMID 38558141 Get It

ImportanceFrontotemporal lobar degeneration (FTLD) is relatively rare, behavioral and motor symptoms increase travel burden, and standard neuropsychological tests are not sensitive to early-stage disease. Remote smartphone-based cognitive assessments could mitigate these barriers to trial recruitment and success, but no such tools are validated for FTLD.ObjectiveTo evaluate the reliability and validity of smartphone-based cognitive measures for remote FTLD evaluations.Design, Setting, and ParticipantsIn this cohort study conducted from January 10, 2019, to July 31, 2023, controls and participants with FTLD performed smartphone application (app)–based executive functioning tasks and an associative memory task 3 times over 2 weeks. Observational research participants were enrolled through 18 centers of a North American FTLD research consortium (ALLFTD) and were asked to complete the tests remotely using their own smartphones. Of 1163 eligible individuals (enrolled in parent studies), 360 were enrolled in the present study; 364 refused and 439 were excluded. Participants were divided into discovery (n = 258) and validation (n = 102) cohorts. Among 329 participants with data available on disease stage, 195 were asymptomatic or had preclinical FTLD (59.3%), 66 had prodromal FTLD (20.1%), and 68 had symptomatic FTLD (20.7%) with a range of clinical syndromes.ExposureParticipants completed standard in-clinic measures and remotely administered ALLFTD mobile app (app) smartphone tests.Main Outcomes and MeasuresInternal consistency, test-retest reliability, association of smartphone tests with criterion standard clinical measures, and diagnostic accuracy.ResultsIn the 360 participants (mean [SD] age, 54.0 [15.4] years; 209 [58.1%] women), smartphone tests showed moderate-to-excellent reliability (intraclass correlation coefficients, 0.77-0.95). Validity was supported by association of smartphones tests with disease severity (r range, 0.38-0.59), criterion-standard neuropsychological tests (r range, 0.40-0.66), and brain volume (standardized β range, 0.34-0.50). Smartphone tests accurately differentiated individuals with dementia from controls (area under the curve [AUC], 0.93 [95% CI, 0.90-0.96]) and were more sensitive to early symptoms (AUC, 0.82 [95% CI, 0.76-0.88]) than the Montreal Cognitive Assessment (AUC, 0.68 [95% CI, 0.59-0.78]) (z of comparison, −2.49 [95% CI, −0.19 to −0.02]; P = .01). Reliability and validity findings were highly similar in the discovery and validation cohorts. Preclinical participants who carried pathogenic variants performed significantly worse than noncarrier family controls on 3 app tasks (eg, 2-back β = −0.49 [95% CI, −0.72 to −0.25]; P < .001) but not a composite of traditional neuropsychological measures (β = −0.14 [95% CI, −0.42 to 0.14]; P = .32).Conclusions and RelevanceThe findings of this cohort study suggest that smartphones could offer a feasible, reliable, valid, and scalable solution for remote evaluations of FTLD and may improve early detection. Smartphone assessments should be considered as a complementary approach to traditional in-person trial designs. Future research should validate these results in diverse populations and evaluate the utility of these tests for longitudinal monitoring.
Fusion‐driven cutaneous and superficial mesenchymal and adnexal tumors—A clinicopathologic and molecular study of 15 cases, including a novel case of ACTB::ZMIZ2‐rearranged adnexal carcinoma
Johnson, Emma F. , Wieland, Carrie N., Camilleri, Michael , Kajdacsy‐Balla, Andre , Oliveira, André M. , Halling, Kevin C. , Gupta, Sounak , Guo, Ruifeng , Dehner, Carina A, Guo, Ruifeng , Dehner, Carina

Mayo Clinic

Journal of Cutaneous Pathology | April 1, 2024 | Volume: 51 | Issue: 7 | Pages: 538-548

10.1111/cup.14610 | PMID 38556256 Get It

AbstractBackgroundWhile the list of fusion‐driven soft tissue neoplasms is expanding rapidly, their importance among cutaneous and superficial mesenchymal and adnexal neoplasms remains poorly understood. This challenge is especially evident in cases with ambiguous histopathology that are difficult to classify based on morphology.AimsOur goal was to investigate the benefits of next‐generation sequencing in diagnosing complex cutaneous neoplasms.Materials & MethodsDepartmental archives were searched for fusion‐driven cutaneous neoplasms. Slides were retrieved and clinical information including follow‐up was obtained.ResultsFifteen cases occurred in eight female and seven male patients, with a median age of 26 years (range: 1–83) at diagnosis. Tumors involved the extremities (9), scalp (5), and head and neck (1). Predominant features included myoepithelial (5), nested spindled with clear cytoplasm (2), atypical adnexal/squamoid (2), small round blue cell (2), cellular spindled (3), and fibrohistiocytic morphology (1). Most frequently encountered fusions involved EWSR1 (6) fused to ERG (1), FLI1 (1), CREB1 (2), CREM (1), PBX3 (1), followed by PLAG1 (4) with LIFR (2), TRPS1 (1) and CHCHD7. Additional fusions encountered were YAP1::NUTM1, EML4::ALK, SS18::SSX1 (2), and a novel fusion: ACTB::ZMIZ2. Integration of histologic features and molecular findings led to final diagnoses of primary cutaneous Ewing sarcoma (2), soft tissue myoepithelioma (4), cutaneous syncytial myoepithelioma (1), cutaneous adnexal carcinoma (1), porocarcinoma (1), inflammatory myofibroblastic tumor (1), synovial sarcoma (2), clear cell sarcoma (2), and angiomatoid fibrous histiocytoma (1).Discussion and conclusionOur results show that fusion testing can be a helpful diagnostic tool, especially in cases with unusual or uncommon morphology in superficial sites. Furthermore, it can allow for the identification of potential therapeutic targets in some instances.
Radioligand therapies in meningioma: Evidence and future directions
Mair, Maximilian J. , Wen, Patrick Y. , Preusser, Matthias , Albert, Nathalie L. , Wen, Patrick Yung , Preusser, Matthias , Tabouret, Emeline , Johnson, Derek R. , Sulman, Erik P.

Mayo Clinic

Neuro-Oncology | March 29, 2024 | Volume: 26 | Issue: Supplement_9 | Pages: S215-S228

10.1093/neuonc/noae069 | PMID 38702966 Get It

Abstract Meningiomas are the most common intracranial neoplasms in adults. While most meningiomas are cured by resection, further treatment by radiotherapy may be needed, particularly in WHO grades 2 and 3 tumors which have an increased risk of recurrence, even after conventional therapies. Still, there is an urgent need for novel therapeutic strategies after the exhaustion of local treatment approaches. Radionuclide therapies combine the specificity of tumor-specific antibodies or ligands with the cytotoxic activity of radioactive emitters. Alongside this, integrated molecular imaging allows for a noninvasive assessment of predictive biomarkers as treatment targets. Whereas the concept of “theranostics” has initially evolved in extracranial tumors such as thyroid diseases, neuroendocrine tumors, and prostate cancer, data from retrospective case series and early phase trials underscore the potential of this strategy in meningioma. This review aims to explore the available evidence of radionuclide treatments and ongoing clinical trial initiatives in meningioma. Moreover, we discuss optimal clinical trial design and future perspectives in the field, including compound- and host-specific determinants of the efficacy of “theranostic” treatment approaches.
Large-scale network analysis of the cerebrospinal fluid proteome identifies molecular signatures of frontotemporal lobar degeneration
Saloner, Rowan , Staffaroni, Adam M. , Dammer, Eric B. , Johnson, Erik C. B. , Wise, Amy B. , Heuer, Hilary W. , Forsberg, Leah K. , Lago, Argentina Lario , Webb, Julia D, Kramer, Joel H. , Li, Jingyao , Sivasankaran, Rajeev , Seyfried, Nicholas T. , Yokoyama, Jennifer S. , Grinberg, Lea T. , Ljubenkov, Peter A. , Brushaber, Danielle , Considine, Ciaran , Day, Gregory S. , Faber, Kelley , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hales, Chadwick M. , Huey, Edward D. , Kornak, John , Lee, Suzee, Mendez, Mario F. , Miyagawa, Toji , Pascual, Belén , Paulson, Henry L. , Petrucelli, Leonard , Ramos, Eliana Marisa , Rascovsky, Katya, Savica, Rodolfo , Snyder, Allison , Sullivan, A. Campbell , Vandebergh, Marijne , Rosen, Howie, Boxer, Adam L. , Casaletto, Kaitlin B. , Staffaroni, Adam M , Hansson, Oskar , Sivasankaran, Rajeev , Yokoyama, Jennifer , Spina, Salvatore , Grinberg, Lea , VandeVrede, Lawren , Brushaber, Danielle , Day, Gregory S , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Galasko, Douglas , Geschwind, Daniel , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Lapid, Maria I. , Litvan, Irene , Mendez, Mario , Pascual, Belen , Roberson, Erik , Snyder, Allison , Tartaglia, Maria Carmela , Vandebergh, Marijne , Boeve, Brad , Paulson, Henry L , Dammer, Eric B

Mayo Clinic

No container title available | March 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4103685/v1 | PMID 38585969 Get It

Abstract The pathophysiological mechanisms driving disease progression of frontotemporal lobar degeneration (FTLD) and corresponding biomarkers are not fully understood. We leveraged aptamer-based proteomics (> 4,000 proteins) to identify dysregulated communities of co-expressed cerebrospinal fluid proteins in 116 adults carrying autosomal dominant FTLD mutations (C9orf72, GRN, MAPT) compared to 39 noncarrier controls. Network analysis identified 31 protein co-expression modules. Proteomic signatures of genetic FTLD clinical severity included increased abundance of RNA splicing (particularly in C9orf72 and GRN) and extracellular matrix (particularly in MAPT) modules, as well as decreased abundance of synaptic/neuronal and autophagy modules. The generalizability of genetic FTLD proteomic signatures was tested and confirmed in independent cohorts of 1) sporadic progressive supranuclear palsy-Richardson syndrome and 2) frontotemporal dementia spectrum syndromes. Network-based proteomics hold promise for identifying replicable molecular pathways in adults living with FTLD. ‘Hub’ proteins driving co-expression of affected modules warrant further attention as candidate biomarkers and therapeutic targets.
Real-World Effectiveness of Ustekinumab in Ulcerative Colitis in a United States Multicenter Cohort Consortium
Yarur, Andrés , Ungaro, Ryan C. , Huang, Katherine , Wang, Wenfei , Sasankan, Priya , Zulqarnain, Mir, Johnson, Amanda M. , Bader, Geoffrey , Kay, Carl , Costable, Nicholas , Dulaney, David , Fenster, Marc, Beniwal‐Patel, Poonam , Syal, Gaurav , Cohen, Benjamin L., Yarur, Andres J , Ungaro, Ryan , Loftus, Edward, Deepak, Parakkal , Patel, Anish A , Loftus, Edward V. , Pekow, Joel , Deepak, Parakkal

Mayo Clinic

Inflammatory Bowel Diseases | March 26, 2024 | Volume: 31 | Issue: 1 | Pages: 131-139

10.1093/ibd/izae058 | PMID 38531068 Get It

Abstract Background Pivotal trials have shown that ustekinumab is effective in ulcerative colitis (UC). However, the population included in these trials do not represent the cohort of patients treated in the real world. In this study, we aimed to describe the effectiveness and safety of ustekinumab in a clinical cohort of patients with UC. Methods We performed a multicenter retrospective cohort study and included patients with active UC starting ustekinumab. Variables collected included demographics, clinical data, and disease activity (measured using partial Mayo score [PMS] and endoscopic Mayo score) at follow-up. The primary outcomes were cumulative rates of steroid-free clinical and biochemical remission (SFCBR), defined as a PMS <2 while off steroids and a normal C-reactive protein and/or fecal calprotectin. Results A total of 245 patients met inclusion criteria. The median time of follow-up was 33 (interquartile range, 17-53) weeks, and 214 (87.3%) had previous exposure to a biologic and/or tofacitinib. Rates of SFCBR, clinical remission, and endoscopic remission at 6 and 12 months were 12.0% (n = 16 of 139), 29.0% (n = 71 of 175), and 18.0% (n = 7 of 39), and 23.8% (n = 15 of 63), 54.3% (n = 57 of 105), and 31.0% (n = 9 of 29), respectively. Non-Hispanic White race, higher baseline PMS, and the use of concomitant corticosteroids were independently associated with failure to achieve SFCBR. Of the 73 that were dose escalated, 28.4% did not respond, 49.3% experienced a benefit, and 21.6% achieved remission. Conclusions In a population enriched with refractory UC, ustekinumab was well tolerated and induced remission in a significant number of patients. Larger studies with a longer follow-up are warranted.
Intracranial findings in spontaneous intracranial hypotension: Does the severity of abnormalities correspond with certainty and/or multifocality of cerebrospinal fluid leaks?
Benson, John C. , Mark, Ian T. , Madhavan, Ajay A. , Johnson‐Tesch, Benjamin A., Kim, Dong Kun , Brinjikji, Waleed , Verdoorn, Jared T. , Johnson-Tesch, Benjamin, Diehn, Felix E. , Verdoorn, Jared T , Benson, John , Mark, Ian , Madhavan, Ajay A , Carr, Carrie M.

Mayo Clinic

The Neuroradiology Journal | March 25, 2024 | Volume: 37 | Issue: 4 | Pages: 468-472

10.1177/19714009241242645 | PMID 38525966 Get It

Background and Purpose Spontaneous intracranial hypotension (SIH) is caused by spinal cerebrospinal fluid (CSF) leaks. This study assessed whether the certainty and/or multifocality of CSF leaks is associated with the severity of intracranial sequelae of SIH. Materials and Methods A retrospective review was completed of patients with suspected SIH that underwent digital subtraction myelogram (DSM) preceded by brain MRI. DSMs were evaluated for the presence or absence of a CSF leak, categorized both as positive/negative/indeterminate and single versus multifocal. Brain MRIs were assessed for intracranial sequelae of SIH based on two probabilistic scoring systems (Dobrocky and Mayo methods). For each system, both an absolute “numerical” score (based on tabulation of findings) and “categorized” score (classification of probability) were tabulated. Results 174 patients were included; 113 (64.9%) were female, average age 52.0 ± 14.3 years. One or more definite leaks were noted in 76 (43.7%) patients; an indeterminate leak was noted in 22 (12.6%) patients. 16 (16.3%) had multiple leaks. There was no significant difference in the severity of intracranial findings between patients with a single versus multiple leaks ( p values ranged from .36 to .70 using categorized scores and 0.22–0.99 for numerical scores). Definite leaks were more likely to have both higher categorized intracranial scores (Mayo p = .0008, Dobrocky p = .006) and numerical scores ( p = .0002 for Mayo and p = .006 for Dobrocky). Conclusions Certainty of a CSF leak on diagnostic imaging is associated with severity of intracranial sequelae of SIH, with definite leaks having significantly more intracranial findings than indeterminate leaks. Multifocal leaks do not cause greater intracranial abnormalities.